Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110).
Clarke DF, Acosta EP, Cababasay M, Wang J, Chain A, Teppler H, Popson S, Graham B, Smith B, Hazra R, Calabrese K, Bryson Y, Spector SA, Lommerse J, Mirochnick M; IMPAACT P1110 Protocol Team.
Clarke DF, et al. Among authors: graham b.
J Acquir Immune Defic Syndr. 2020 May 1;84(1):70-77. doi: 10.1097/QAI.0000000000002294.
J Acquir Immune Defic Syndr. 2020.
PMID: 31913995
Free PMC article.
Clinical Trial.